ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.473,63
1,32%
S&P 500
5.744,61
-0,01%
Dow Jones
42.458,36
0,67%
Euro vs US Dollar
1,11588
-0,15%
Bitcoin
66.129,15
1,45%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) News

NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NKTR
DatumZeitQuelleÜberschriftSymbolFirma
25/09/202409h30PR Newswire (US)Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024NASDAQ:NKTRNektar Therapeutics
03/09/202415h00PR Newswire (US)Nektar Management to Present at Upcoming Investor ConferencesNASDAQ:NKTRNektar Therapeutics
21/08/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
21/08/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
21/08/202403h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
19/08/202422h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
19/08/202422h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
19/08/202421h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
08/08/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
08/08/202422h15PR Newswire (US)Nektar Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:NKTRNektar Therapeutics
02/08/202400h00PR Newswire (US)Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
15/06/202400h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
14/06/202422h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
12/06/202415h30PR Newswire (US)Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024NASDAQ:NKTRNektar Therapeutics
06/06/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
06/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NKTRNektar Therapeutics
05/06/202423h30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NKTRNektar Therapeutics
31/05/202400h00PR Newswire (US)Nektar Management to Present at Upcoming Investor ConferencesNASDAQ:NKTRNektar Therapeutics
28/05/202422h51Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NKTRNektar Therapeutics
21/05/202403h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
21/05/202403h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
21/05/202403h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
17/05/202422h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
17/05/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
17/05/202422h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
13/05/202422h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
09/05/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
09/05/202422h15PR Newswire (US)Nektar Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:NKTRNektar Therapeutics
03/05/202400h00PR Newswire (US)Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
22/03/202419h00PR Newswire (US)Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:NKTRNektar Therapeutics
 Showing the most relevant articles for your search:NASDAQ:NKTR

Kürzlich von Ihnen besucht

TG
432
Arbor Metals
TG
BAS
BASF
TG
LHA
Deutsche Lufthansa
AMEX
SPY
SPDR S&P 500
NYSE
KO
Coca Cola
TG
D7G
Nel ASA
AMEX
XLF
Financial Select Sector
FX
EURUSD
Euro vs US Dollar
NYSE
DIS
Walt Disney
USOTC
ADDYY
Adidas (QX)
FX
EURJPY
Euro vs Yen
USOTC
BASFY
BASF (QX)
NYSE
XOM
Exxon Mobil
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten